Key result
Cilostazol administration significantly attenuated angiotensin II-induced dilatation of abdominal aortas and reduced AAA incidence in apolipoprotein E-deficient mice.
Why the study?
Does cilostazol prevent angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice?
Population
Male apolipoprotein E-deficient mice
Comparison
Diet containing cilostazol starting 1 week prior… vs Normal diet with angiotensin II infusion
Design
Preclinical
Follow-up
5 weeks (1 week pretreatment plus 4 weeks infusion)
Authors
Loading...
Cilostazol merits human AAA trials; leaves open whether PDE3 inhibition alters clinical progression.
Does cilostazol prevent angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice?
Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysm formation in a mouse model via anti-inflammatory effects, suggesting a potential therapeutic option.
Umebayashi et al. (2018) studied Abdominal aortic aneurysm. Cilostazol vs. Normal diet was evaluated on Dilatation of abdominal aortas and AAA incidence. Cilostazol administration significantly attenuated angiotensin II-induced dilatation of abdominal aortas and reduced AAA incidence in apolipoprotein E-deficient mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: